Functionalized Nanoparticles for Viral Clearance via Phagocytosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies face challenges in effectively targeting and neutralizing a wide range of viral strains, particularly airborne viruses like SARS-CoV-2, due to their ability to evade host cell receptors and develop resistance.
Innovation Solution
Development of functionalized nano- or microparticles with a diameter of 400 to 700 nm, surface-immobilized virus-binding peptides or small molecules, such as minibinders, that bind to target viruses with nano- to picomolar affinity, facilitating phagocytosis for viral clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral therapies target host cell receptors, then they can block viral entry, but viruses can evade these receptors and develop resistance
Solution Approach 1:
Instead of using host cell receptors to block viral entry, the invention uses synthetic virus-binding peptides that mimic receptor function but are not susceptible to viral evasion. These peptides bind directly to viral surface proteins with high affinity, inverting the traditional approach by placing the binding function in the therapeutic agent rather than relying on fixed host receptors.
Solution Approach 2:
The patent introduces nanoparticle carriers as intermediaries that present multiple virus-binding peptides simultaneously. These nanoparticles act as mediators between the therapeutic peptides and viral particles, enabling multivalent binding that significantly enhances neutralization efficiency and prevents viral escape through single-point mutations.
2Speed
If virus-binding peptides are used to saturate viral envelope proteins, then viral entry is decelerated, but viruses are not actively neutralized and cleared
Solution Approach 1:
The nanoparticles pre-concentrate multiple virus-binding peptides on their surface before encountering viral particles. This preliminary arrangement of binding sites allows for immediate multivalent binding upon virus contact, rapidly neutralizing the virus and directing it toward cellular clearance mechanisms rather than allowing gradual saturation during the entry process.
Solution Approach 2:
The invention replaces the gradual chemical saturation process with a mechanical capture system. The nanoparticle physically captures viral particles through multiple simultaneous binding events, mechanically preventing further viral entry steps and facilitating opsonization and phagocytic clearance by immune cells.
3Ease of operation
If nanoparticles are used to deliver antiviral agents, then targeted delivery is improved, but the particles must be small enough for delivery yet large enough to be phagocytosed
Solution Approach 1:
The nanoparticle system exhibits dynamic size characteristics: the core particles are small (20-100 nm) for efficient delivery and tissue penetration, but upon binding multiple viral particles, the overall complex grows to larger sizes (200 nm to several micrometers) that are optimally recognized and phagocytosed by macrophages and other immune cells. This dynamic size transition resolves the contradiction between delivery efficiency and clearance effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The functionalized particles effectively compete with host cell receptors for virus binding, triggering macrophage-mediated phagocytosis and achieving significant viral clearance, while also potentially serving as diagnostic tools for virus detection.
Implementation Method 1
the virus-binding peptide and/or the virus-binding small molecule binds to the at least one target virus with nano- to picomolar affinity
Implementation Method 2
the functionalized nano- or microparticle has aggregates with targeted viral particles to initiate phagocytosis
Implementation Method 3
triggering macrophage-mediated phagocytosis and achieving significant viral clearance
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 2D~2E
AI summary
The present invention relates to functionalized nano- or microparticles of suitable size and shape, comprising a nano- or microparticle and at least one virus-binding peptide and/or virus-binding small molecule immobilized onto the surface of the nano- or microparticle. These nano- or microparticle forms aggregates with targeted viral particles to initiate phagocytosis, thereby achieving viral clearance. The present invention further relates to uses of the functionalized nano- or microparticles in virus detection, therapy and diagnosis.